跳至主要内容

The Drug Regimen Prescribed for Sickle Cell Patients Attending a Clinic in Kumasi, Ghana, in a Period of One Year

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=51608#.VHKBcWfHRK1

Objective: In order to manage the varied pathophysiological features of sickle cell disease (SCD), an array of drugs has to be used. The specific drugs used, however, depend on the locality. This study was aimed at finding out the drug regimen prescribed by clinicians to sickle cell disease patients who attended a Sickle Cell Clinic in Kumasi, Ghana. Method: The setting for the study is the Sickle Cell Clinic at the Komfo Anokye Teaching Hospital, Ghana, and a questionnaire was used as the study instrument. Information on drug prescription on each day of clinic visit was extracted from the medical records of the patients. Results: The drugs prescribed were “routine drugs” for SCD patients, analgesics, narcotics, anti-malarials, antibiotics, haematinics and miscellaneous drugs. The top ten commonly prescribed drugs were folic acid, diclofenac, ibuprofen, B-complex, routine drugs, artesunate/amodiaquin, paracetamol, penicillin V, amoxiclav and zincovit. Conclusion: Within the year, the drugs prescribed included those that could prevent vitamin and zinc deficiency due to continuing haemolysis, those that could mitigate the pain and inflammation from vaso-occlusion and reperfusion injury, as well as antibiotics to combat infections. Being a malarial-endemic region, prophylaxis with daraprim and symptomatic malaria fever therapy were common practices. This study has thus shown that the well-being of SCD patients in our typical tropical terrain, depends on haematinic vitamin/mineral supplements, anti-malarials, analgesics-anti-inflammatory, antipyretics and antibiotics.
Cite this paper
Nsiah, K. , Osei-Akoto, A. and Ansong, D. (2014) The Drug Regimen Prescribed for Sickle Cell Patients Attending a Clinic in Kumasi, Ghana, in a Period of One Year. Open Journal of Blood Diseases, 4, 50-57. doi: 10.4236/ojbd.2014.44007. 
 

[1] Bonds, D.R. (2003) Three Decades of Innovation in the Management of Sickle Cell Disease: The Road to Understanding the Sickle Cell Disease Phenotype. Blood Reviews, 19, 99-110.
http://dx.doi.org/10.1016/j.blre.2004.04.002
[2] Dampier, C. and Setty, B.N.Y. (2004) Vaso-Constriction in Children with Sickle Cell Disease: Clinical Characteristics and Biologic Correlations. Journal of Pediatric Hematology/Oncology, 29, 785-790.
[3] Benjamin, L.J. (2001) The Nature and Management of Acute Pain Episode in Sickle Cell Disease. In: Forget, B.G., Higgs, D., Nagel, R.L. and Steinberg, M.H., Eds., Diseases of Hemoglobin, Cambridge University Press, Cambridge, 671-710.
[4] de Franceschi, L., Finco, G., Vassanelli, A., Zaia, B., Ischia, S. and Corrocher, R. (2004) A Pilot Study on the Efficacy of Ketorolac plus Tramadol Infusion Combined with Erythrocytapheresis in the Management of Acute Severe Vaso-Occlusive Crises and Sickle Cell Pain. Haematologica, 489, 1389-1391.
[5] Krisnamoorthy, P., Alyaarubi, S., Abish, A., Gale, M., Abuquerque, P. and Jabado, N. (2006) Primary Hyperparathyroidism Mimicking Vaso-Occlusive Crises in Sickle Cell Disease. Journal of Pediatrics, 118, e537-e539.
http://dx.doi.org/10.1542/peds.2006-0337
[6] Aliyu, Z.K., Tumblin, A.R. and Kato, G.J. (2006) Current Therapy of Sickle Cell Disease. Haematologica, 91, 7-10.
[7] Jison, M.L., Munson, P.J., Barb, J.F., Suffredini, A.F., Talwar, S., Logun, C., Raghavachori, N., Beigel, J.H., Danner, R.L. and Gladwin, M.T. (2004) Blood Mononuclear Cell Gene Expression Profiles Characterize the Oxidant, Hemolytic, and Inflammatory Stress in the Expression of Sickle Cell Disease. Blood, 104, 270-280.
http://dx.doi.org/10.1182/blood-2003-08-2760
[8] Hankins, J. and Aygun, B. (2009) Pharmacotherapy in Sickle Cell Disease—State of the Art and Future Prospects. British Journal of Haematology, 145, 296-308.
http://dx.doi.org/10.1111/j.1365-2141.2009.07602.x
[9] Payan, D.G. and Katzung, B.G. (1992) Nonsteroidal Anti-Inflammatory Drugs: Nonopioid Analgesics; Drugs Used in Gout. In: Katzung, B.G., Ed., Basic and Clinical Pharmacology, 6th Edition, Appleton and Lange, Norwalk, Connecticut, 535-557.
[10] Gringauz, A. (1997) Introduction to Medicinal Chemistry. Wiley-VCH, New York, 144,205,235,251,265-266.
[11] Lindenbaum, J. and Klipstein, F.A. (1963) Folic Acid Deficiency in Sickle Cell Disease. New England Journal of Medicine, 269, 875-882.
http://dx.doi.org/10.1056/NEJM196310242691701
[12] Lindenbaum, J. (1997) Workshop on Human Folate Requirements Folic Acid Biochemistry and Physiology in Relation to Human Nutritional Requirement. National Academy of Sciences, Washington DC, 256-276.
[13] Yardurmian, A. and Crawley, C. (2001) Sickle Cell Disease. Clinical Medicine, 1, 441-451.
http://dx.doi.org/10.7861/clinmedicine.1-6-441
[14] Sadarangani, M., Makani, J., Komba, A.N., Ajala-Agbo, T., Newton, C.R., Marsh, K. and Williams, T.N. (2009) An Observational Study of Children in Kilifi, Kenya. British Journal of Haematology, 146, 675-682.
http://dx.doi.org/10.1111/j.1365-2141.2009.07771.x
[15] Prasad, A.S. (1993) Clinical Spectrum of Human Zinc Deficiency. In: Prasad, A.S., Ed., Biochemistry of Zinc, Plenum, New York, 219-258.
http://dx.doi.org/10.1007/978-1-4757-9444-1_11
[16] Prasad, A.S. (1997) [Editorial] Malnutrition in Sickle Cell Disease Patients. American Journal of Clinical Nutrition, 66, 423-424.
[17] Lambright-Eckker, J.A. and Stimmel-Fair, J.M. (1996) Pharmacology Essentials. WB Saunders Company, Philadelphia, 179,207.
[18] World Health Organisation (2003) The Africa Malaria Report.
http://www.afro.who.int                                   eww141124lx
[19] Konotey-Ahulu, F.I.D (1991) The Sickle Disease Patient. Macmillan, London.
标签：

评论

发表评论

此博客中的热门博文

Does Immigration Promote the Investment of the Monopolistic Firm?

In the present paper, we examine the effect of increasing uncertainty of immigrants’ growth on the optimal timing of investment of a firm that has a monopolistic power over the labor market. It is revealed that when the uncertainty of immigrants’ growth is more than a threshold level, increasing uncertainty of immigrants’ growth accelerates the optimal timing of firms’ investment and enhances the economic growth, even if the uncertainty of immigrants’ growth is formulated by the geometric Brownian motion, which is in sharp contrast to the standard result that an increase in the uncertainty postpones the optimal timing. With an increase in the immigrants over the past ten years, workforces in the host countries have been growing significantly to the extent that the immigrants represent 70% of the increase in the workforce in Europe, and 47% in the United States as OECD indicates. In the present paper, we attempted to investigate the effect of increased uncertainty caused by the growi...
发表评论
阅读全文

Education Policy Implementation: A Mechanism for Enhancing Primary Education Development in Zanzibar

Education is one of the fundamental rights of individuals; therefore, the government of a country needs to develop and strengthen educational policy and quality as well as to ensure that everyone has equal access to basic education. The improvement of access and quality of education in the world is becoming as an essential factor in development, whereas the basic education (primary school), is acknowledged as a foundation of the higher educational development for every country. To fulfill this goal, governments introduce several policies and procedures; however, it requires some reforms and participation from the politician, policymakers, and other stakeholders to re-examine educational policy so that it can lead to multiplication and betterment of the reforms. Educational reforms actually focus on accountability. A positive educational development and reform is very challenging and needs more effort and strategy on how to use and utilize the resources effectively as such it can achie...
发表评论
阅读全文